Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide

Molecular Pharmaceutics
Yi CuiJoseph Irudayaraj

Abstract

In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy. A poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) based nanoconjugate was fabricated to encapsulate decitabine and achieved a better therapeutic response in GBM cells than that with the free drug. After synthesis, the highly efficient uptake process and intracellular dynamics of this nanoconjugate were monitored by single-molecule fluorescence tools. Our experiments demonstrated that, under an acidic pH due to active glycolysis in cancer cells, the PLGA-PEG nanovector could release the conjugated decitabine at a faster rate, after which the hydrolyzed lactic acid and glycolic acid would further acidify the intracellular microenvironment, thus providing positive feedback to increase the effective drug concentration and realize growth inhibition. In temozolomide-resistant GBM cells, decitabine can potentiate the cytotoxic DNA alkylation by counteracting cytosine methylation and reactivating tumor suppressor genes, such as p53 and p21. Owing to the excellent internalization and endolysosomal e...Continue Reading

References

Sep 1, 1989·Circulation Research·S B Coade, J D Pearson
Feb 27, 1999·Biophysical Journal·U MesethH Vogel
Jul 2, 1999·Biophysical Journal·Y ChenE Gratton
Nov 4, 2000·Methods in Cell Biology·G JuanZ Darzynkiewicz
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
Aug 3, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jayanth PanyamVinod Labhasetwar
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marta BrellFrancesc Graus
Nov 24, 2005·International Journal of Pharmaceutics·Donald E Owens, Nicholas A Peppas
Nov 1, 2007·Nature Methods·Sally A KimPetra Schwille
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Brian D SlaughterRong Li
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Apr 22, 2008·International Journal of Cancer. Journal International Du Cancer·Carlo Stresemann, Frank Lyko
Nov 28, 2008·Molecular Pharmaceutics·Peisheng XuYoon Yeo
Feb 24, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·S AmatoriM Fanelli
May 12, 2009·Seminars in Cancer Biology·Raman P Nagarajan, Joseph F Costello
Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Sep 17, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Svetlana GelperinaJörg Kreuter
Nov 17, 2009·Methods in Enzymology·Bo YuL James Lee
Dec 18, 2009·Current Medicinal Chemistry·L ZhangC-M Huang
Apr 30, 2010·International Journal of Oncology·Atsuo YoshinoKouhei Tsumoto
Jun 22, 2010·Small·Santosh AryalLiangfang Zhang
Jul 16, 2010·Journal of Colloid and Interface Science·Murali Mohan YallapuSubhash C Chauhan
Sep 18, 2010·Trends in Pharmacological Sciences·Xiaojing YangPeter A Jones
Oct 23, 2010·Advanced Drug Delivery Reviews·Sarbari Acharya, Sanjeeb K Sahoo
Feb 23, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabienne DanhierVéronique Préat
Feb 24, 2012·Nucleosides, Nucleotides & Nucleic Acids·Vijaya L DamarajuZeen Tong
Sep 5, 2012·Nature Reviews. Genetics·Holger Heyn, Manel Esteller
Apr 16, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Dong Yeok ShinYung Hyun Choi
Aug 27, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Yi CuiJoseph Irudayaraj
Oct 18, 2013·The New England Journal of Medicine·Sunit Das, Philip A Marsden
Jan 15, 2014·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Darshana S JainRajiv P Gude
Feb 27, 2014·Molecular Cancer Therapeutics·Erika L MoenLucy A Godley

❮ Previous
Next ❯

Citations

Sep 11, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Basil MujokoroMasood Khosravani
Apr 4, 2017·ACS Applied Materials & Interfaces·Mubashir HussainJintao Zhu
May 13, 2020·Cellular Oncology (Dordrecht)·Patryk KrzeminskiNorma C Gutiérrez
Jul 17, 2020·Frontiers in Oncology·Anthony QuaglianoSonali P Barwe
Oct 28, 2019·Cancers·Jong-Whi Park, Şevin Turcan
Mar 21, 2020·Journal of Neuro-oncology·Matthew GallittoRaymund L Yong
Dec 11, 2020·Nano Convergence·Julia SalapaJoseph Irudayaraj
Aug 15, 2017·Biochemical Pharmacology·Zachary BensonMasoud H Manjili

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.